Johnson and Johnson 2013 Annual Report Download - page 58

Download and view the complete annual report

Please find page 58 of the 2013 Johnson and Johnson annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 84

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84

A summary of the restricted share units and performance share units activity under the Plans as of December 29, 2013 is
presented below:
(Shares in Thousands)
Outstanding
Restricted
Share Units
Outstanding
Performance
Share Units
Shares at January 2, 2011 29,734
Granted 11,478
Issued (8,300)
Canceled/forfeited (1,886)
Shares at January 1, 2012 31,026
Granted 12,197 327
Issued (9,278) –
Canceled/forfeited (2,111) (42)
Shares at December 30, 2012 31,834 285
Granted 10,582 1,290
Issued (10,078) –
Canceled/forfeited (1,721) (40)
Shares at December 29, 2013 30,617 1,535
The average fair value of the restricted share units granted was $65.90, $58.93 and $55.90 in 2013, 2012 and 2011,
respectively, using the fair market value at the date of grant. The fair value of restricted share units was discounted for
dividends, which are not paid on the restricted share units during the vesting period. The fair value of restricted share units
settled was $569.2 million, $483.2 million and $458.9 million in 2013, 2012 and 2011, respectively.
The weighted average fair value of the performance share units granted was $73.42 and $55.01 in 2013 and 2012,
calculated using the weighted average fair market value for each of the three component goals at the date of grant.
The fair values for the sales and earnings per share goals of each performance share unit were estimated on the date of
grant using the fair market value of the shares at the time of the award discounted for dividends, which are not paid on the
performance share units during the vesting period. The fair value for the relative total shareholder return goal of each
performance share unit was estimated on the date of grant using the Monte Carlo valuation model. No performance share
units vested in 2013 and 2012.
18. Segments of Business and Geographic Areas
Sales to Customers
(Dollars in Millions) 2013 2012 2011
Consumer –
United States $5,162 5,046 5,151
International 9,535 9,401 9,732
Total 14,697 14,447 14,883
Pharmaceutical –
United States 13,948 12,421 12,386
International 14,177 12,930 11,982
Total 28,125 25,351 24,368
Medical Devices and Diagnostics –
United States 12,800 12,363 11,371
International 15,690 15,063 14,408
Total 28,490 27,426 25,779
Worldwide total $71,312 67,224 65,030
48 •Johnson & Johnson 2013 Annual Report